Analytical ultracentrifuge
Analytical ultracentrifuge
批准号:
429433916
负责人:
金额:
$0.0万
依托单位国家:
德国
项目类别:
Major Research Instrumentation
财政年份:
2020
资助国家:
德国
项目状态:
未结题
起止时间:
2019-12-31 至 --
中文摘要
自生物物理化学研究所和相关的结构生物化学研究设施成立以来,汉诺威一直是具有国际地位的分析超离心(AUC)的所在地。我们的AUC设备不仅是MHH相关人员的重要研究工具,也是全国许多科学家的重要研究工具。借助AUC,可以在不受固相干扰的情况下,对溶液中蛋白质、核酸和配体的相互作用进行定性和定量研究。目前使用的设备是2008年的贝克曼库尔特蛋白质实验室XL-I,不再是最先进的设备。在运行的第12年中,它的使用越来越受到停机时间、高维修和不断增加的维护成本的限制。新的Beckman Coulter Optima AUC模型将光学元件移出真空室。这有利于高性能光学元件的集成,并能够同时检测多达三种不同的光学器件。沉降可以在高达20个波长下检测,具有更高的扫描速度和分辨率。这可以改进具有不同吸收光谱的分子的定量相互作用研究。更高的时间分辨率有助于敏感蛋白的研究,并使更大的蛋白质复合物的沉降跟踪具有显著增加的选择性。
英文摘要
Since the foundation of the Institute for Biophysical Chemistry and the associated research facility for Structural Biochemistry, Hannover has been a location for analytical ultracentrifugation (AUC) of international standing. Our AUC equipment is an important research tool not only for interested parties at MHH, but it is also used by many scientists nationwide. With the help of AUC, interactions of proteins, nucleic acids and ligands can be qualitatively and quantitatively investigated in solution without the influence of interfering solid phases. The device currently in use, a Beckman Coulter ProteomeLab XL-I from 2008, is no longer state-of-the-art. In the 12th year of operation, its usage is increasingly restricted by downtimes, high repair and increasing maintenance costs. The new Beckman Coulter Optima AUC model has the optical components moved out of the vacuum chamber. This facilitates the integration of high-performance optical components and enables simultaneous detection with up to three different optics. Sedimentation can be detected at up to 20 wavelengths with higher scan speed and resolution. This allows improved quantitative interaction studies of molecules with different absorption spectra. The higher temporal resolution facilitates the investigation of sensitive proteins and enables the tracking of the sedimentation of larger protein complexes with significantly increased selectivity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金